13-Hydroxylergotrile
Pharmaceutical compound
From Wikipedia, the free encyclopedia
13-Hydroxylergotrile, also known as 2-chloro-6-methyl-13-hydroxyergoline-8β-acetonitrile, is a dopamine receptor agonist of the ergoline family.[1][2] It is an active metabolite of the never-marketed antiparkinsonian agent lergotrile (LY-79907).[1][2] The drug has been found to be 100-fold more potent as a dopamine receptor agonist than lergotrile itself in vitro.[1][2] 13-Hydroxylergotrile was first described in the scientific literature by 1978.[1]
| Clinical data | |
|---|---|
| Other names | 2-Chloro-6-methyl-13-hydroxyergoline-8β-acetonitrile |
| Drug class | Dopamine receptor agonist |
| ATC code |
|
| Chemical and physical data | |
| Formula | C17H17ClN3O |
| Molar mass | 314.79 g·molâ1 |
| 3D model (JSmol) | |
| |
| |